Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-Methyl-N-[3-(6-Phenyl[1,2,4]Triazolo[4,3-B]Pyridazin-3-Yl)Phenyl]Acetamide is a synthetic small molecule belonging to the phenylpyridazine class. It has been studied as an experimental compound and is referenced in chemical and pharmacological databases but does not have an established clinical use or approved indication. The compound has demonstrated binding affinity for the bacterial cell division protein ZipA from Escherichia coli (strain K12), suggesting potential antibacterial activity through inhibition of bacterial cell division machinery. However, there are no reports of its development for human therapeutic use or detailed mechanism of action in humans.[2][6]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-Methyl-N-[3-(6-Phenyl[1,2,4]Triazolo[4,3-B]Pyridazin-3-Yl)Phenyl]Acetamide.